ScyFIX
HCID Member | Medical Devices & Tech  Advamed Member
570 W 78TH ST # 2001
Chanhassen, MN 55317 USA
phone: 612-964-6500
fax: 952-975-0616
Symbol Private
Founded 2002
Employees
www.scyfix.org
Research Sector Medical Devices & Tech
Summary Description
Micro-current stimulation device stimulates recovery of diseased eye tissue
Management
Mr. Thomas Harold, CEO and Founder
Keywords
ophthalmology, macular degeneration, blindness, electrostimulation, retinitis pigmentosa, Stargardt's disease, glaucoma, low vision

Comment | Printable Version | Aug. 19, 2008
If you work for ScyFIX and want to update this profile, click here

Description
ScyFIX is developing sight-saving technologies for people suffering from degenerative eye diseases for which there are currently no cures or therapies. ScyFIX offers the only patented Micro Current Stimulation device for the treatment of Macular Degeneration, Stargardt's disease, Retinitis Pigmentosa, and other degenerative eye diseases.
Products / Services
The ScyFIX 600 micro current stimulation device facilitates increased brightness, decreased fogginess, improved visual acuity, enhanced color perception, and reduction of blind spots. Micro-current stimulation has also been proven to expand the visual field for individuals diagnosed with Macular Degeneration and Retinitis Pigmentosa.
Technology / Differentiation
Research suggests that ScyFIX's electrical stimulation approximates the level of electrical activity present in a healthy eye, stimulating recovery in diseased or dormant cells. Studies have shown that micro-current stimulation can improve vision for 85% of patients suffering from Macular Degeneration, 83% of those suffering from Stargardt's disease, and 66% of those suffering from Retinitis Pigmentosa.
Market / Customers
Macular Degeneration (MD) is a major cause of eyesight deterioration in older age groups, affecting millions of people. It is estimated that 5% of the world's population will develop a form of MD. Currently there are no FDA approved treatments for Dry AMD or Retinitis Pigmentosa. The untreated U.S. market for Dry AMD includes over 7 million people; the aging of the baby boomer generation will lead to an estimated 50% increase in the prevalence of age-related degenerative eye diseases by 2020. Penetration of 5% into the large American market would yield $3.2 billion in associated revenues.
Status
ScyFIX is continuing its trial for treating Dry Age-Related Macular Degeneration (ARMD) and Open-Angle Glaucoma studies using Micro Current Neuromodulation (MCN) at Aditya Joyt Eye Hospital Pvt., Ltd. in India and is completing a Retinitis Pigmentosa (RP) study at LV Prasad, for which the FDA has granted HUD (Humanitarian Use Device) approval.


2008-10-11-2096